Q2 EPS Estimate for Viridian Therapeutics Reduced by Analyst

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at HC Wainwright decreased their Q2 2025 earnings estimates for Viridian Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($1.09) per share for the quarter, down from their prior forecast of ($0.99). HC Wainwright currently has a “Buy” rating and a $34.00 target price on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($3.91) EPS, Q2 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.09) EPS, FY2027 earnings at ($2.84) EPS, FY2028 earnings at ($1.82) EPS and FY2029 earnings at ($0.01) EPS.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year.

Several other research analysts have also recently issued reports on the stock. Needham & Company LLC reduced their target price on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a report on Wednesday. Royal Bank of Canada lowered their target price on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday. The Goldman Sachs Group reduced their price target on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, JMP Securities lowered their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $36.70.

Viridian Therapeutics Stock Performance

VRDN opened at $12.54 on Friday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics has a 12-month low of $9.90 and a 12-month high of $27.20. The firm has a 50 day moving average of $13.71 and a two-hundred day moving average of $17.49. The firm has a market capitalization of $1.02 billion, a PE ratio of -2.91 and a beta of 0.57.

Institutional Trading of Viridian Therapeutics

Several institutional investors have recently modified their holdings of VRDN. FMR LLC lifted its stake in Viridian Therapeutics by 6.2% in the 4th quarter. FMR LLC now owns 11,881,912 shares of the company’s stock valued at $227,776,000 after buying an additional 698,434 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company’s stock valued at $88,087,000 after acquiring an additional 174,952 shares during the last quarter. Deep Track Capital LP lifted its position in shares of Viridian Therapeutics by 20.6% in the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company’s stock valued at $86,701,000 after acquiring an additional 771,796 shares in the last quarter. Tang Capital Management LLC lifted its position in shares of Viridian Therapeutics by 11.1% in the fourth quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company’s stock valued at $47,789,000 after acquiring an additional 250,000 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Viridian Therapeutics by 3.8% in the fourth quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company’s stock worth $43,842,000 after acquiring an additional 84,255 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.